<DOC>
	<DOCNO>NCT00607087</DOCNO>
	<brief_summary>Primary objective : To demonstrate superiority insulin glulisine insulin aspart insulin lispro administer external pump term unexplained hyperglycemia and/or infusion set occlusion . Main Secondary objective : To compare insulin glulisine , insulin aspart insulin lispro : - Unexplained hyperglycemia - Infusion set occlusion - Hypoglycemic episodes,7-point blood glucose profile - Episodes significant ketosis and/or risk level impend diabetic ketoacidosis - Time change infusion set - HbA1c ( Glycosylated hemoglobin ) - Overall safety : incidence adverse event</brief_summary>
	<brief_title>Effect Insulin Glulisine Compared Insulin Aspart Insulin Lispro When Administered Continuous Subcutaneous Insulin Infusion ( CSII ) Specific Pump Parameters Patient With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The maximal duration study participation patient 41 week one day , split : - 2-week screening period , - 39-week treatment period : 3 treatment period 13 week crossover alternative regimen , include dose adjustment period 1 week begin period ( sequence1 : insulin glulisine , insulin aspart , insulin lispro ; sequence2 : insulin aspart , insulin lispro , insulin glulisine ; sequence 3 : insulin lispro , insulin glulisine , insulin aspart ) - follow-up period 24 hour .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetic subject Treated insulin least 2 year CSII least 6 month Using insulin ( insulin glulisine , insulin aspart insulin lispro ) CSII least 3 month external pump compatible 3 short act insulin analogue use study Using type infusion set ( catheter cannula ) least 3 month Performing least 3 blood glucose control per day HbA1c &lt; 8.5 % Body mass index ( BMI ) &lt; 35 kg/m² Ability willingness perform blood glucose ketone monitor use Sponsorprovided combine glucose ketone meter patient diary home Diabetes Type 1 Total daily dose insulin great 90 U/day Using insulin pump require prefilled cartridge History infection infusion site require drainage last 3 month History severe episode ketosis require hospitalization last 6 month Active proliferative retinopathy , define photocoagulation vitrectomy occurrence 6 month prior visit 1 , unstable ( rapidly progress ) retinopathy may require photocoagulation surgical treatment study . An ophthalmoscopic examination perform 2 year prior study entry Pregnancy ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method ) breastfeed Treatment systemic corticosteroid medication know influence insulin sensitivity 3 month prior visit 1 Treatment antidiabetic drug insulin 3 month prior visit 1 Likelihood require treatment study permit Treatment investigational product 30 day prior visit 1 History sensitivity study drug drug similar chemical structure Presence condition ( medical , include clinically significant abnormal laboratory test , psychological , social geographical ) actual anticipate Investigator feel would compromise patient safety limit his/her successful participation study Night shift worker Impaired renal function show serum creatinine ≥1.5 mg/dL ( 133 μmol/L ) ≥1.4 mg/dL ( 124 μmol/L ) men woman , respectively Impaired hepatic function show Alanine aminotransferase ( ALT ) and/or Aspart aminotransferase ( AST ) great three time upper limit normal range ) Alcohol drug abuse last year Mental condition render patient unable understand nature , scope possible consequence study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>